Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations

Vinay K. Godena, Nicholas Brookes-Hocking, Annekathrin Moller, Gary Shaw, Matthew Oswald, Rosa M. Sancho, Christopher C. J. Miller, Alexander J. Whitworth () and Kurt J. De Vos ()
Additional contact information
Vinay K. Godena: University of Sheffield, Firth Court, Western Bank
Nicholas Brookes-Hocking: Institute of Psychiatry, Psychology and Neuroscience, King’s College London
Annekathrin Moller: Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield
Gary Shaw: Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield
Matthew Oswald: University of Sheffield, Firth Court, Western Bank
Rosa M. Sancho: Institute of Psychiatry, Psychology and Neuroscience, King’s College London
Christopher C. J. Miller: Institute of Psychiatry, Psychology and Neuroscience, King’s College London
Alexander J. Whitworth: University of Sheffield, Firth Court, Western Bank
Kurt J. De Vos: Centre for Membrane Interactions and Dynamics, University of Sheffield

Nature Communications, 2014, vol. 5, issue 1, 1-11

Abstract: Abstract Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson’s disease. LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules. Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson’s disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known. Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo. In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase αTAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport. In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior. Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson’s disease.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/ncomms6245 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6245

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6245

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().